


In the Claims:

Claims 1-12 (Canceled)

Add New Claims 13-23.

13. (New) compound of the structural formula I:



Formula I

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof:

wherein,

R represents hydrogen, or C₁₋₆ alkyl;X represents -(CHR₇)_pCO-;Y represents -CO(CH₂)_n-;

Q represents N;

R_w represents H, C₁₋₆ alkyl, -C(O)C₁₋₆ alkyl, -C(O)OC₁₋₆ alkyl, -SO₂N(R)₂, -SO₂C₁₋₆ alkyl, -SO₂C₆₋₁₀ aryl, NO₂, CN or -CON(R)₂;R₂ represents hydrogen, C₁₋₁₀ alkyl, -(CH₂)_nC₃₋₈ cycloalkyl, said alkyl, optionally substituted with 1-3 groups selected from R^a;R₃ represents hydrogen, C₁₋₁₀ alkyl, -(CH₂)_nC₃₋₈ cycloalkyl, said alkyl, optionally substituted with 1-3 groups of R^a;or, when Q is N, R₂ and R₃ taken together with the intervening N atom form a 4-10 membered heterocyclic carbon ring optionally interrupted by 1-2 atoms of O, S, C(O) or

R₄ and R₅ independently represent hydrogen, C₁₋₆ alkoxy, OH, C₁₋₆ alkyl, SO_qC₁₋₆ alkyl, COC₁₋₆ alkyl, COOR, SO₃H, -O(CH₂)_nN(R)₂, -O(CH₂)_nCO₂R, CF₃, OCF₃, -N(R)₂, nitro, cyano, C₁₋₆ alkylamino, or halogen; and

R₆ represents hydrogen, C₁₋₁₀ alkyl, -(CH₂)_nC₆₋₁₀ aryl, NR_cR_d, -NR(CH₂)_nC₆₋₁₀ aryl, -N((CH₂)_nC₆₋₁₀ aryl)₂, -(CH₂)_nC₃₋₁₀ heterocyclyl, -NR(CH₂)_nC₃₋₁₀ heterocyclyl, -N((CH₂)_nC₃₋₁₀ heterocyclyl)₂, (C₆₋₁₀ aryl)O-, -(CH₂)_nC₃₋₈ cycloalkyl, -COOR, -C(O)CO₂R, said aryl, heterocyclyl and alkyl optionally substituted with 1-3 groups selected from R^a, wherein the R^a(s) can be attached to any carbon atom or heteroatom selected from N and S;

R_c and R_d independently represent H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₁₋₆ alkylSR, -(CH₂)_nO(CH₂)_mOR, -(CH₂)_nC₁₋₆ alkoxy, -(CH₂)_nC₃₋₈ cycloalkyl;

or R_c and R_d taken together with the intervening N atom form a 4-10 membered heterocyclic carbon ring optionally interrupted by 1-2 atoms of O, S, C(O) or NR, and optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from R^a;

R₇ represents hydrogen, C₁₋₆ alkyl, -(CH₂)_nCOOR or -(CH₂)_nN(R)₂,

R₈ represents -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_n 3-10 heterocyclyl, C₁₋₆ alkoxy – or (CH₂)_nC₆₋₁₀ aryl said heterocyclyl, or aryl optionally substituted with 1-3 groups selected from R^a;

R^a represents F, Cl, Br, I, CF₃, N(R)₂, NO₂, CN, -O-, -COR₈, -CONHR₈, -CON(R₈)₂, -O(CH₂)_nCOOR, -NH(CH₂)_nOR, -COOR, -OCF₃, CF₂CH₂OR, -NHCOR, -SO₂R, -SO₂NR₂, -SR, (C₁-C₆ alkyl)O-, -(CH₂)_nO(CH₂)_mOR, -O(CH₂)_nO(CH₂)_mOR, -(CH₂)_nC₁₋₆ alkoxy, (aryl)O-, -(CH₂)_nOH, (C₁-C₆ alkyl)S(O)_m-, H₂N-C(NH)-, (C₁-C₆ alkyl)C(O)-, (C₁-C₆ alkyl)OC(O)NH-, -(C₁-C₆ alkyl)NR_w(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₁-C₆ alkyl)O(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₁-C₆ alkyl)S(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₁-C₆ alkyl)-C₃₋₁₀ heterocyclyl-R_w, -(CH₂)_n-Z¹-C(=Z²)N(R)₂, -(C₂₋₆ alkenyl)NR_w(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₂₋₆ alkenyl)O(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₂₋₆ alkenyl)S(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₂₋₆ alkenyl)-C₃₋₁₀ heterocyclyl-R_w, -(C₂₋₆ alkenyl)-Z¹-C(=Z²)N(R)₂, -(CH₂)_nSO₂R, -(CH₂)_nSO₃H, -C₃₋

10cycloalkyl, C₆₋₁₀ aryl, C₃₋₁₀ heterocyclyl, C₂₋₆ alkenyl, and C_{1-C₁₀} alkyl, said alkyl, alkenyl, alkoxy, heterocyclyl and aryl optionally substituted with 1-3 groups selected from C_{1-C₆} alkyl, halogen, CN, NO₂, -(CH₂)_nOH, CON(R)₂ and COOR;

Z¹ and Z² independently represents NR_w, O, CH₂, or S;

m is 0-3;

n is 0-3;


p is 0-3 and









q is 0-2.












14. (New) A compound according to Claim 13 wherein R₆ is (CH₂)_nC₆₋₁₀ aryl, (CH₂)_nC₃₋₁₀ heterocyclyl, NR_cR_d or (CH₂)_nC₃₋₈ cycloalkyl, said aryl, heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R^a.











15. (New) A compound of Table 1 through 4 which is:

Table 1



R1	R2	R3
H	Phenyl	
H	Phenyl	
H	Phenyl	
H	Phenyl	
H	Phenyl	
H	Phenyl	
H	Phenyl	
OMe	Phenyl	

R1	R2	R3
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	

OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	




OMe	Isopropyl	
-----	-----------	---

Table 2




R2	R3	R2	R3

Table 3



R3	R3	R3

Table 4



R2	R3	R2	R3

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

16. (New) A method for treating ocular hypertension or glaucoma comprising administration to a patient in need of such treatment a therapeutically effective amount of a compound of Claim 13.

17. (New) A method for treating macular edema, macular degeneration, increasing retinal and optic nerve head blood velocity, increasing retinal and optic nerve oxygen tension, and/or a neuroprotective effect comprising administration to a patient in need of such treatment a pharmaceutically effective amount of a compound of Claim 13; or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

18. (New) A method of preventing repolarization or hyperpolarization of a mammalian cell containing potassium channel or a method of treating Alzheimer's Disease, depression, cognitive disorders, and/or arrhythmia disorders in a patient in need thereof comprising administering a pharmaceutically effective amount of a compound according to Claim 13, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

19. (New) A method of treating diabetes in a patient in need thereof comprising administering a pharmaceutically effective amount of a compound according to Claim 13, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

20. (New) A composition comprising a compound of formula I of Claim 13 and a pharmaceutically acceptable carrier.

21. (New). The composition according to Claim 20 wherein the compound of formula I is applied as a topical formulation, said topical formulation administered as a solution or suspension and optionally containing xanthan gum or gellan gum.

22. (New) A composition according to Claim 20 wherein an active ingredient belonging to the group consisting of: beta-adrenergic blocking agent, parasympatho-mimetic agent, sympathomimetic agent, carbonic anhydrase inhibitor, EP4

agonist, a prostaglandin or derivative thereof, hypotensive lipid, neuroprotectant, and/or 5-HT₂ receptor agonist is optionally added.

23. (New) A composition according to Claim 22 wherein the beta-adrenergic blocking agent is timolol, betaxolol, levobetaxolol, carteolol, or levobunolol; the parasympathomimetic agent is pilocarpine; the sympathomimetic agent is epinephrine, brimonidine, iopidine, clonidine, or para-aminoclonidine, the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, metazolamide or brinzolamide; the prostaglandin is latanoprost, travaprost, unoprostone, rescula, or S1033, the hypotensive lipid is lumigan, the neuroprotectant is eliprodil, R-eliprodil or memantine; and the 5-HT₂ receptor agonist is 1-(2-aminopropyl)-3-methyl-1H-imidazol-6-ol fumarate or 2-(3-chloro-6-methoxy-indazol-1-yl)-1-methyl-ethylamine.